StockWatch
·
Biotechnology: Pharmaceutical Preparations
Management ChangeNov 18, 2026, 05:01 PM

Teva Pharma R&D Chief Dr. Eric Hughes Departs; Search Underway

AI Summary

Teva Pharmaceutical Industries Ltd. announced that Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, will be leaving the company. David Gardiner, MD, will serve as the interim lead for R&D while Teva conducts a search for a permanent successor. Dr. Hughes will remain with Teva for a few months to ensure a smooth transition. The company stated that its R&D strategy and priorities remain unchanged, with a focus on achieving $6–7 billion in innovative medicines revenue by 2030.

Key Highlights

  • Dr. Eric Hughes, EVP, Global R&D and Chief Medical Officer, is departing Teva.
  • David Gardiner, MD, appointed interim R&D lead during the search for a successor.
  • Teva's R&D strategy and priorities remain unchanged.
  • Company reaffirms ambition to generate $6–7 billion in innovative medicines revenue by 2030.